Imexpharm Corporation (HOSE:IMP)

Market Cap	7.73T
Revenue (ttm)	2.45T
Net Income (ttm)	333.14B
Shares Out	154.01M
EPS (ttm)	2,163.10
PE Ratio	23.21
Forward PE	22.94
Dividend	500.00 (1.00%)
Ex-Dividend Date	Jun 9, 2025

Volume	51,173
Average Volume	87,266
Open	50,100
Previous Close	50,100
Day's Range	49,700 - 50,400
52-Week Range	36,100 - 56,500
Beta	0.69
RSI	58.31
Earnings Date	Jan 16, 2026

About Imexpharm

Imexpharm Corporation manufactures, processes, trades in, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, cardiovascular, ophthalmology, musculoskeletal system, analgesic-anti-inflammatory- antipyretics, respiratory system, anti-histamines, anti-allergy, central nervous system, digestive system, diabetes, and anti-parasitic, as well as vitamins and minerals, and supplements. It is also involved in the import and export of medical equipment and supplies, ...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 7.11%.